← Back to Clinical Trials
Recruiting NCT06869343

NCT06869343 Early Versus Delayed Rehabilitation After Reverse Total Shoulder Arthroplasty for Proximal Humerus Fracture

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06869343
Status Recruiting
Phase
Sponsor University of Virginia
Condition Orthopedic Disorder
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2025-05-19
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Physical Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2025-05-19 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Proximal humerus fractures can be a debilitating injury in the elderly, impacting the ability to function independently or complete activities of daily living due to pain and restricted shoulder motion. Evidence has shown that reverse total shoulder arthroplasty (rTSA) is an effective option to improve pain and function for patients with acute displaced proximal humerus fractures. Given that patients undergoing rTSA for proximal humerus fractures typically experience worse functional outcomes, worse patient-reported outcomes, and higher rates of complication compared to those with elective indications for surgical intervention, it is critical to determine a secure path to recovery for these patients after surgery. Early rehabilitation has been proposed to be safe and effective for patients who undergo rTSA for elective indications; however, there is a paucity of research evaluating safety and effectiveness of timing of rehabilitation for rTSA patients in the trauma setting. Currently, there exists a great variability in postoperative rehabilitation protocols across orthopaedic practices. This study's objective is to determine the safety and effectiveness of early postoperative rehabilitation on the outcomes and postoperative complications of patients undergoing rTSA for proximal humerus fractures in order to provide more specific recommendations for this patient population.

Eligibility Criteria

Inclusion Criteria: * aged 50-85 undergo reverse Total Shoulder Arthroplasty by a single surgeon for proximal humerus fractures Exclusion Criteria: * previous rTSA to ipsilateral shoulder * undergoing elective rTSA * Prisoners * unwilling to be randomized * unwilling or unable to attend follow up visits

Contact & Investigator

Central Contact

Lori Elder

✉ LJE5U@uvahealth.org

📞 434-924-8570

Principal Investigator

Seth Yarboro, MD

PRINCIPAL INVESTIGATOR

University of Virginia

Frequently Asked Questions

Who can join the NCT06869343 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Orthopedic Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06869343 currently recruiting?

Yes, NCT06869343 is actively recruiting participants. Contact the research team at LJE5U@uvahealth.org for enrollment information.

Where is the NCT06869343 trial being conducted?

This trial is being conducted at Charlottesville, United States.

Who is sponsoring the NCT06869343 clinical trial?

NCT06869343 is sponsored by University of Virginia. The principal investigator is Seth Yarboro, MD at University of Virginia. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology